Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity

G Magliocco, J Desmeules, A Matthey… - British Journal of …, 2021 - Wiley Online Library
Background and Purpose Individualized assessment of cytochrome P450 2D6 (CYP2D6)
activity is usually performed through phenotyping following administration of a probe drug to …

[HTML][HTML] Practice of CYP450 genotyping and phenotyping in children in a real-life setting

F Rodieux, Y Daali, V Rollason, CF Samer… - Frontiers in …, 2023 - frontiersin.org
Pharmacokinetics varies widely between children. Many factors play an important role in this
variability, such as ontogeny, pharmacogenetics, gender, comorbidities, and drug-drug …

Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6‐hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood …

G Magliocco, J Desmeules, CF Samer… - Clinical and …, 2022 - Wiley Online Library
The suitability of the endogenous 6‐hydroxymelatonin/melatonin urinary metabolic ratio as a
surrogate for the paraxanthine/caffeine ratio to predict cytochrome P450 1A2 (CYP1A2) …

[PDF][PDF] Colchicine Poisoning Cases in a Pediatric Intensive Care Unit

E Süzen-Orhan, E Botan, E Gün, H Özen… - Pediatr Emerg …, 2022 - researchgate.net
Objectives: Colchicine intoxication is rare but potentially fatal. The toxic dose of colchicine is
not well established; it has been reported that major toxicity starts after doses of 0.5 mg/kg …

Colchicine poisoning cases in a pediatric intensive care unit: a twenty-year study

E Süzen-Orhan, E Botan, E Gün, H Özen… - Pediatric …, 2022 - journals.lww.com
Objectives Colchicine intoxication is rare but potentially fatal. The toxic dose of colchicine is
not well established; it has been reported that major toxicity starts after doses of 0.5 mg/kg …

Biomarkers of CYP3A4 and CYP2D6 metabolism in vivo

BMT Wollmann - 2024 - duo.uio.no
There is extensive interindividual variability in drug response and tolerability. This is to a
major extent caused by differences in the metabolic capacities of the enzymes CYP3A4 and …

Personalized medicine and drug metabolism

A Talevi, CL Bellera - The ADME Encyclopedia: A Comprehensive Guide …, 2022 - Springer
The passive targeting of nanocarriers comprises the achievement of their site-specific
delivery based solely on their capacity to exploit physiological and/or pathological …